

Pfizer/BioNTech COVID-19 Vaccine – Expanded emergency use authorization

- On December 9, 2021, the <u>FDA announced</u> an expanded emergency use authorization (EUA) for the <u>Pfizer/BioNTech COVID-19 vaccine</u>, for a single booster dose to individuals 16 years of age and older who have completed a primary series with Pfizer-BioNTech COVID-19 vaccine or Comirnaty[®].
 - Previously, a single booster dose was indicated for individuals 18 years and older.
- Additionally, the Pfizer/BioNTech COVID-19 vaccine is authorized under EUA for:
 - A 2-dose primary series to individuals 12 through 15 years of age
 - A 2-dose primary series to individuals 5 thought 11 years of age (orange cap)
 - A third primary series dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise and
 - A single booster dose to individuals 18 years of age and older who have completed primary vaccination with a different authorized COVID-19 vaccine.
- Comirnaty is an FDA-approved COVID-19 vaccine that is indicated for active immunization as a 2-dose primary series to prevent COVID-19 in individuals 16 years of age and older.
- The EUA for a single booster dose of the Pfizer-BioNTech COVID-19 vaccine for individuals 16 and 17 years of age is based on the FDA's previous analysis of immune response data that supported use of a booster dose in individuals 18 years of age and older.
- The FDA has determined that the benefits of a single booster dose of the Pfizer-BioNTech COVID-19 vaccine or Comirnaty outweigh the risks of myocarditis and pericarditis in individuals 16 and 17 years of age to provide continued protection against COVID-19 and the associated serious consequences that can occur including hospitalization and death.
- The recommended dose of the Pfizer/BioNTech COVID-19 vaccine for a booster dose in individuals 16 years of age and older is a single dose (0.3 mL) administered at least 6 months after completing a primary series of the Pfizer/BioNTech COVID-19 vaccine or Comirnaty.
 - This is the same dose as the primary series for the Pfizer/BioNTech COVID-19 vaccine.

What's Next:

- As a reminder of the process, FDA issues the authorization, ACIP reviews the data and recommends the proper use, the CDC Director must then verify the ACIP recommendations before they become official.
- The CDC has not yet scheduled an Advisory Committee on Immunization Practices (ACIP) meeting.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.